The role of single-incision laparoscopic peritoneal exploration in the management of patients with peritoneal metastases.
Laparoendoscopic single-site surgery
Minimally invasive surgery
Peritoneal cancer index
Peritoneal carcinomatosis
Peritoneoscopy
Single-incision laparoscopic surgery
Journal
Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
20
11
2018
accepted:
15
07
2019
pubmed:
20
7
2019
medline:
29
5
2021
entrez:
20
7
2019
Statut:
ppublish
Résumé
The outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) depends on the extent of peritoneal metastases (PM) and the completeness of cytoreduction (CCR). The role of preoperative assessment of PM is to identify potential candidates for CRS/HIPEC and to prevent unwarranted laparotomy for those who are not. Laparoscopy has been utilized for that purpose but with concerns related to technical difficulties and risk of trocar site metastases. Single-incision laparoscopic peritoneal exploration (SILPE) has not yet been evaluated in this setting. This single-center retrospective study examined patients from January 2011 to December 2015 who underwent SILPE for diagnosis and staging of PM. Preoperative, intraoperative, and postoperative data were collected. For the patients who underwent subsequent laparotomy, a comparison between SILPE and laparotomy findings was made. A total of 183 SILPE were performed. Primary sites were mostly colorectal in 72 cases (39.3%) and gastric in 47 (25.7%). Overall, 157 patients (85.8%) had at least one prior abdominal surgery and 48 (26.2%) had 3 or more. SILPE was successfully achieved in 90.2% of the cases. Two (1.2%) intraoperative complications and five (3%) postoperative complications were observed. Eighty-one patients had laparotomy, with a median of 27 days between SILPE and laparotomy (4-162 days). The peritoneal carcinomatosis index PCI was 9.7 ± 7.5 at SILPE, and 13.5 ± 9.6 at laparotomy. The positive predictive value of SILPE to predict CCR was 79.5%. SILPE sensitivity was 75% and specificity 97%. The lowest sensitivity was in regions 9-12 ranging from 44 to 53%. SILPE can be safely incorporated in the management of patients with PM. It is a safe and feasible staging tool, allowing for preventing unwarranted laparotomy for patients not deemed candidate for CRS/HIPEC. Even though it may underestimate PCI, SILPE accurately predicts the possibility of CCR.
Sections du résumé
BACKGROUND
The outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) depends on the extent of peritoneal metastases (PM) and the completeness of cytoreduction (CCR). The role of preoperative assessment of PM is to identify potential candidates for CRS/HIPEC and to prevent unwarranted laparotomy for those who are not. Laparoscopy has been utilized for that purpose but with concerns related to technical difficulties and risk of trocar site metastases. Single-incision laparoscopic peritoneal exploration (SILPE) has not yet been evaluated in this setting.
METHODS
This single-center retrospective study examined patients from January 2011 to December 2015 who underwent SILPE for diagnosis and staging of PM. Preoperative, intraoperative, and postoperative data were collected. For the patients who underwent subsequent laparotomy, a comparison between SILPE and laparotomy findings was made.
RESULTS
A total of 183 SILPE were performed. Primary sites were mostly colorectal in 72 cases (39.3%) and gastric in 47 (25.7%). Overall, 157 patients (85.8%) had at least one prior abdominal surgery and 48 (26.2%) had 3 or more. SILPE was successfully achieved in 90.2% of the cases. Two (1.2%) intraoperative complications and five (3%) postoperative complications were observed. Eighty-one patients had laparotomy, with a median of 27 days between SILPE and laparotomy (4-162 days). The peritoneal carcinomatosis index PCI was 9.7 ± 7.5 at SILPE, and 13.5 ± 9.6 at laparotomy. The positive predictive value of SILPE to predict CCR was 79.5%. SILPE sensitivity was 75% and specificity 97%. The lowest sensitivity was in regions 9-12 ranging from 44 to 53%.
CONCLUSION
SILPE can be safely incorporated in the management of patients with PM. It is a safe and feasible staging tool, allowing for preventing unwarranted laparotomy for patients not deemed candidate for CRS/HIPEC. Even though it may underestimate PCI, SILPE accurately predicts the possibility of CCR.
Identifiants
pubmed: 31321535
doi: 10.1007/s00464-019-06984-8
pii: 10.1007/s00464-019-06984-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2040-2049Références
Semin Surg Oncol. 2001 Mar;20(2):109-21
pubmed: 11398204
Surg Endosc. 2017 Feb;31(2):743-751
pubmed: 27324331
N Engl J Med. 2018 Apr 5;378(14):1363-1364
pubmed: 29617590
Surg Endosc. 2017 Oct;31(10):4034-4043
pubmed: 28283763
Ann Surg. 2016 Dec;264(6):1110-1115
pubmed: 27828822
J Clin Oncol. 2003 Oct 15;21(20):3737-43
pubmed: 14551293
Surg Endosc. 2016 Sep;30(9):3808-15
pubmed: 26659231
In Vivo. 2009 Jan-Feb;23(1):187-90
pubmed: 19368148
Eur J Surg Oncol. 2016 Apr;42(4):558-66
pubmed: 26856956
J Surg Oncol. 2008 Sep 15;98(4):224-7
pubmed: 18726881
Ann Surg Oncol. 2012 Nov;19(12):3737-44
pubmed: 22805859
J Clin Oncol. 2010 Jan 1;28(1):63-8
pubmed: 19917863
Ann Surg Oncol. 2015 May;22(5):1658-63
pubmed: 25245127
Br J Surg. 2018 May;105(6):663-667
pubmed: 29579322
J Surg Oncol. 2015 Jun;111(8):1035-40
pubmed: 26040443
Br J Surg. 2013 Jan;100(2):285-92
pubmed: 23124619
JAMA Surg. 2014 Feb;149(2):170-5
pubmed: 24352601
World J Surg Oncol. 2014 Aug 21;12:270
pubmed: 25145962
Ann Surg Oncol. 2015 Apr;22(4):1267-73
pubmed: 25319578
Eur J Surg Oncol. 2006 Feb;32(1):65-71
pubmed: 16290055
Ann Surg Oncol. 2008 Sep;15(9):2426-32
pubmed: 18521686
J Gastrointest Surg. 2014 May;18(5):1024-31
pubmed: 24577736
Ann Surg Oncol. 2016 May;23(5):1461-7
pubmed: 26542584
Eur J Surg Oncol. 2005 Jun;31(5):540-3
pubmed: 15922890
J Visc Surg. 2018 Sep;155(4):293-303
pubmed: 29602696
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
J Visc Surg. 2015 Jun;152(3):147-8
pubmed: 26027893
Ann Surg. 2013 Jun;257(6):1065-71
pubmed: 23299520
Ann Surg. 2010 Jan;251(1):101-6
pubmed: 19838105
Ann Surg. 2011 Aug;254(2):289-93
pubmed: 21709543
Cancer Treat Res. 1996;82:359-74
pubmed: 8849962
Ann Surg Oncol. 2015 Apr;22(4):1236-42
pubmed: 25319584
J Visc Surg. 2017 Dec;154(6):430-435
pubmed: 29153426
World J Gastrointest Oncol. 2010 Jan 15;2(1):31-5
pubmed: 21160814
Ann Surg Oncol. 2009 May;16(5):1295-303
pubmed: 19252950
J Visc Surg. 2015 Nov;152(5):285-91
pubmed: 26115889
Ann Surg Oncol. 2007 Jan;14(1):128-33
pubmed: 17072675
J Visc Surg. 2017 Apr;154(2):133-134
pubmed: 28395955